Vitality Watch

Dossier pubmed review 14-sep-2026
Narrative review or expert overview without new data

Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review.

Key claim: GLP-1 receptor agonists reduce body weight and major adverse cardiovascular events across high-risk patients with type 2 diabetes and with overweight or obesity without diabetes, including significant CV risk reduction with semaglutide in SELECT partly independent of weight loss.

Abstract

Obesity is a rapidly increasing global health challenge that is strongly linked to the cardiorenometabolic syndrome, cardiovascular morbidity, and mortality. Lifestyle interventions remain the cornerstone of treatment, but average long-term weight loss is modest and durable weight maintenance is often limited. Bariatric surgery is not suitable for all patients, and substantial weight regain occurs in a considerable proportion over time. Glucagon-like peptide‑1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes (T2D), have emerged as potent agents for weight reduction and cardiometabolic risk improvement. By enhancing glucose-dependent insulin secretion, suppressing appetite, improving lipid metabolism, and exerting anti-inflammatory, endothelial, and haemodynamic effects, GLP-1RAs influence multiple pathways relevant to cardiovascular disease.Across large cardiovascular-outcome trials, GLP-1RAs consistently reduce major adverse cardiovascular events (MACE), all-cause mortality, and heart-failure hospitalizations in individuals with T2D. In populations with overweight or obesity without diabetes, semaglutide, as shown in the SELECT trial, has demonstrated significant cardiovascular risk reduction, partly independent of weight loss. Overall, GLP-1RAs represent a therapeutic option for cardiovascular prevention across a broad spectrum of patients at high-risk for or with established CVD. This review provides a comprehensive overview of the pleiotropic cardiovascular effects associated with GLP-1RAs and discusses their potential integration into cardiovascular care.

Why this matters

GLP-1 receptor agonists reduce body weight and major adverse cardiovascular events across high-risk patients with type 2 diabetes and with overweight or obesity without diabetes, including significant CV risk reduction with semaglutide in SELECT partly independent of weight loss.

Source

Link

Briefing card

Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review.
Stage: review · pubmed · 14-sep-2026

GLP-1 receptor agonists reduce body weight and major adverse cardiovascular events across high-risk patients with type 2 diabetes and with overweight or obesity without diabetes, including significant CV risk reduction with semaglutide in SELECT partly independent of weight loss.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s12471-026-02073-3

build build 880 · 2bcef25 · 2026-11-18